Key result
Permissive cardiotoxicity balances managing cancer therapy-related cardiac damage against the risk of interrupting oncologic treatment.
Why the study?
Permissive cardiotoxicity is an evolving clinical practice balancing cancer treatment-associated cardiotoxicities with the risk of interrupting lifesaving cancer therapies, requiring updated frameworks and guidance.
Permissive cardiotoxicity represents an important paradigm shift in cardio-oncology, enabling patients to continue life-saving cancer therapies while their treatment-associated cardiovascular toxicities are actively managed.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“When CTR-CVT is present, the risks and benefits of ongoing cancer therapy must be carefully considered. This decision involves discussions with the patient, their caregivers, and treating health care providers. If the risk-benefit relationship is favorable, a strategy of permissive CTR-CVT may be adopted. This approach allows the continuation of cardiotoxic treatment under close surveillance, accompanied by appropriate cardiovascular therapies, with the goal of optimizing cancer treatment delivery.”
May support continuing cancer therapy with active cardiotoxicity management; leaves open optimal thresholds pending prospective validation.
Permissive cardiotoxicity is an evolving clinical practice pattern that balances the management of cancer treatment‐associated cardiotoxicities with the risk of interrupting lifesaving or life‐extending cancer treatments. This paradigm shift has been catalyzed by advancements in the diagnostic and therapeutic tools available to treating clinicians, as well as a recognition of the consequences of withholding or delaying cancer therapy. Permissive cardiotoxicity has become a central tenet in the practice of cardio‐oncologists; however, recognition and confidence in managing cardiotoxicity is also crucial for the general cardiologist and oncologist due to the growing population of patients with cancer. This review aims to (1) highlight the philosophy of permissive cardiotoxicity, (2) provide a framework for risk stratification of cardiovascular toxicities, (3) describe systems of care considerations for successful implementation of permissive cardiotoxicity, and (4) review the existing literature and guideline recommendations for specific cardiovascular toxicity mitigation.
No takes yet. Share an insight, caveat, or question.
Madnick et al. (2026) conducted a review in Cancer treatment-associated cardiotoxicities. Permissive cardiotoxicity was evaluated. Permissive cardiotoxicity is an evolving clinical practice pattern balancing the management of cancer treatment-associated cardiotoxicities with the risk of interrupting lifesaving cancer therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: